APO Research
Talk to an analyst

APO RESEARCH · REPORT

Live Attenuated Measles Vaccine

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Live Attenuated Measles Vaccine Industry Growth and Trends Forecast to 2032

29 December 2025118 pages

Choose your research edition.

Industry ResearchLive Attenuated Measles Vaccine Industry Research Report 2026132 pages · $2,950 USDIndustry Growth & TrendsGlobal Live Attenuated Measles Vaccine Industry Growth and Trends Forecast to 2032118 pages · $3,450 USDMarket StructureGlobal Live Attenuated Measles Vaccine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032190 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Live Attenuated Measles Vaccine Market Outlook and Growth Opportunities 2026208 pages · $4,250 USDMarket Analysis & ForecastGlobal Live Attenuated Measles Vaccine Market Analysis and Forecast 2026-2032204 pages · $4,950 USD

Market perspective

The global Live Attenuated Measles Vaccine market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Live Attenuated Measles Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Live Attenuated Measles Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Live Attenuated Measles Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Live Attenuated Measles Vaccine include GSK, Bavarian Nordic, CSL Limited, Emergent Biosolutions, Medimmune, Sanofi-Pasteur, Serum Institute of India, Beijing Institute of Biological Products Co., Ltd and Pfizer, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Live Attenuated Measles Vaccine market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Live Attenuated Measles Vaccine market size, estimates, and forecasts are presented in terms of sales volume (K Units) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Live Attenuated Measles Vaccine market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Live Attenuated Measles Vaccine.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global Live Attenuated Measles Vaccine market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Live Attenuated Measles Vaccine Market by Company

GSK

Bavarian Nordic

CSL Limited

Emergent Biosolutions

Medimmune

Sanofi-Pasteur

Serum Institute of India

Beijing Institute of Biological Products Co., Ltd

Pfizer

Lanzhou Institute of Biological Products Co., Ltd

Merck

Novartis

Johnson & Johnson

Shanghai Institute of Biological Products Co., Ltd

Wuhan Institute of Biological Products Co., Ltd

Changchun Qijian Biological Products Co., Ltd

Live Attenuated Measles Vaccine Segment by Type

Liquid

Powder

Live Attenuated Measles Vaccine Segment by Application

Hospital

Clinic

Live Attenuated Measles Vaccine Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Live Attenuated Measles Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Live Attenuated Measles Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Live Attenuated Measles Vaccine.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Live Attenuated Measles Vaccine manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of Live Attenuated Measles Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of Liquid Table 2. Major Company of Powder Table 3. Global Live Attenuated Measles Vaccine Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Global Live Attenuated Measles Vaccine Sales by Type (2021-2026) & (K Units) Table 5. Global Live Attenuated Measles Vaccine Sales Market Share in Volume by Type (2021-2026) Table 6. Global Live Attenuated Measles Vaccine Sales by Type (2021-2026) & (US$ Million) Table 7. Global Live Attenuated Measles Vaccine Sales Market Share in Value by Type (2021-2026) Table 8. Global Live Attenuated Measles Vaccine Price by Type (2021-2026) & (US$/Unit) Table 9. Global Live Attenuated Measles Vaccine Sales by Type (2027-2032) & (K Units) Table 10. Global Live Attenuated Measles Vaccine Sales Market Share in Volume by Type (2027-2032) Table 11. Global Live Attenuated Measles Vaccine Sales by Type (2027-2032) & (US$ Million) Table 12. Global Live Attenuated Measles Vaccine Sales Market Share in Value by Type (2027-2032) Table 13. Global Live Attenuated Measles Vaccine Price by Type (2027-2032) & (US$/Unit) Table 14. North America Live Attenuated Measles Vaccine Sales by Type (2021-2026) & (K Units) Table 15. North America Live Attenuated Measles Vaccine Sales by Type (2021-2026) & (US$ Million) Table 16. Europe Live Attenuated Measles Vaccine Sales by Type (2021-2026) & (K Units) Table 17. Europe Live Attenuated Measles Vaccine Sales by Type (2021-2026) & (US$ Million) Table 18. Asia-Pacific Live Attenuated Measles Vaccine Sales by Type (2021-2026) & (K Units) Table 19. Asia-Pacific Live Attenuated Measles Vaccine Sales by Type (2021-2026) & (US$ Million) Table 20. Latin America Live Attenuated Measles Vaccine Sales by Type (2021-2026) & (K Units) Table 21. Latin America Live Attenuated Measles Vaccine Sales by Type (2021-2026) & (US$ Million) Table 22. Middle East and Africa Live Attenuated Measles Vaccine Sales by Type (2021-2026) & (K Units) Table 23. Middle East and Africa Live Attenuated Measles Vaccine Sales by Type (2021-2026) & (US$ Million) Table 24. Live Attenuated Measles Vaccine Industry Trends Table 25. Live Attenuated Measles Vaccine Industry Drivers Table 26. Live Attenuated Measles Vaccine Industry Opportunities and Challenges Table 27. Live Attenuated Measles Vaccine Industry Restraints Table 28. Global Live Attenuated Measles Vaccine Sales Revenue by Company (US$ Million) & (2021-2026) Table 29. Global Live Attenuated Measles Vaccine Revenue Market Share by Company (2021-2026) Table 30. Global Live Attenuated Measles Vaccine Sales by Company (2021-2026) & (K Units) Table 31. Global Live Attenuated Measles Vaccine Sales Share by Company (2021-2026) Table 32. Global Live Attenuated Measles Vaccine Market Price by Company (2021-2026) & (US$/Unit) Table 33. Global Live Attenuated Measles Vaccine Industry Company Ranking, 2024 VS 2025 VS 2026 Table 34. Global Live Attenuated Measles Vaccine Major Company Production Sites and Headquarters Table 35. Global Live Attenuated Measles Vaccine Company, Product Type & Application Table 36. Global Live Attenuated Measles Vaccine Company Establishment Date Table 37. Global Company Market Concentration Ratio (CR5 and HHI) Table 38. Global Live Attenuated Measles Vaccine by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 39. Global Live Attenuated Measles Vaccine Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 40. Global Live Attenuated Measles Vaccine Sales by Region (2021-2026) & (K Units) Table 41. Global Live Attenuated Measles Vaccine Sales Market Share in Volume by Region (2021-2026) Table 42. Global Live Attenuated Measles Vaccine Sales by Region (2021-2026) & (US$ Million) Table 43. Global Live Attenuated Measles Vaccine Sales Market Share in Value by Region (2021-2026) Table 44. Global Live Attenuated Measles Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 45. Global Live Attenuated Measles Vaccine Sales by Region (2027-2032) & (K Units) Table 46. Global Live Attenuated Measles Vaccine Sales Market Share in Volume by Region (2027-2032) Table 47. Global Live Attenuated Measles Vaccine Sales by Region (2027-2032) & (US$ Million) Table 48. Global Live Attenuated Measles Vaccine Sales Market Share in Value by Region (2027-2032) Table 49. Global Live Attenuated Measles Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2027-2032) Table 50. Global Live Attenuated Measles Vaccine Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 51. Global Live Attenuated Measles Vaccine Sales by Application (2021-2026) & (K Units) Table 52. Global Live Attenuated Measles Vaccine Sales Market Share in Volume by Application (2021-2026) Table 53. Global Live Attenuated Measles Vaccine Sales by Application (2021-2026) & (US$ Million) Table 54. Global Live Attenuated Measles Vaccine Sales Market Share in Value by Application (2021-2026) Table 55. Global Live Attenuated Measles Vaccine Price by Application (2021-2026) & (US$/Unit) Table 56. Global Live Attenuated Measles Vaccine Sales by Application (2027-2032) & (K Units) Table 57. Global Live Attenuated Measles Vaccine Sales Market Share in Volume by Application (2027-2032) Table 58. Global Live Attenuated Measles Vaccine Sales by Application (2027-2032) & (US$ Million) Table 59. Global Live Attenuated Measles Vaccine Sales Market Share in Value by Application (2027-2032) Table 60. Global Live Attenuated Measles Vaccine Price by Application (2027-2032) & (US$/Unit) Table 61. North America Live Attenuated Measles Vaccine Sales by Application (2021-2026) & (K Units) Table 62. North America Live Attenuated Measles Vaccine Sales by Application (2021-2026) & (US$ Million) Table 63. Europe Live Attenuated Measles Vaccine Sales by Application (2021-2026) & (K Units) Table 64. Europe Live Attenuated Measles Vaccine Sales by Application (2021-2026) & (US$ Million) Table 65. Asia-Pacific Live Attenuated Measles Vaccine Sales by Application (2021-2026) & (K Units) Table 66. Asia-Pacific Live Attenuated Measles Vaccine Sales by Application (2021-2026) & (US$ Million) Table 67. Latin America Live Attenuated Measles Vaccine Sales by Application (2021-2026) & (K Units) Table 68. Latin America Live Attenuated Measles Vaccine Sales by Application (2021-2026) & (US$ Million) Table 69. Middle East and Africa Live Attenuated Measles Vaccine Sales by Application (2021-2026) & (K Units) Table 70. Middle East and Africa Live Attenuated Measles Vaccine Sales by Application (2021-2026) & (US$ Million) Table 71. GSK Company Information Table 72. GSK Business Overview Table 73. GSK Live Attenuated Measles Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 74. GSK Live Attenuated Measles Vaccine Product Portfolio Table 75. GSK Recent Development Table 76. Bavarian Nordic Company Information Table 77. Bavarian Nordic Business Overview Table 78. Bavarian Nordic Live Attenuated Measles Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 79. Bavarian Nordic Live Attenuated Measles Vaccine Product Portfolio Table 80. Bavarian Nordic Recent Development Table 81. CSL Limited Company Information Table 82. CSL Limited Business Overview Table 83. CSL Limited Live Attenuated Measles Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 84. CSL Limited Live Attenuated Measles Vaccine Product Portfolio Table 85. CSL Limited Recent Development Table 86. Emergent Biosolutions Company Information Table 87. Emergent Biosolutions Business Overview Table 88. Emergent Biosolutions Live Attenuated Measles Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 89. Emergent Biosolutions Live Attenuated Measles Vaccine Product Portfolio Table 90. Emergent Biosolutions Recent Development Table 91. Medimmune Company Information Table 92. Medimmune Business Overview Table 93. Medimmune Live Attenuated Measles Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 94. Medimmune Live Attenuated Measles Vaccine Product Portfolio Table 95. Medimmune Recent Development Table 96. Sanofi-Pasteur Company Information Table 97. Sanofi-Pasteur Business Overview Table 98. Sanofi-Pasteur Live Attenuated Measles Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 99. Sanofi-Pasteur Live Attenuated Measles Vaccine Product Portfolio Table 100. Sanofi-Pasteur Recent Development Table 101. Serum Institute of India Company Information Table 102. Serum Institute of India Business Overview Table 103. Serum Institute of India Live Attenuated Measles Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 104. Serum Institute of India Live Attenuated Measles Vaccine Product Portfolio Table 105. Serum Institute of India Recent Development Table 106. Beijing Institute of Biological Products Co., Ltd Company Information Table 107. Beijing Institute of Biological Products Co., Ltd Business Overview Table 108. Beijing Institute of Biological Products Co., Ltd Live Attenuated Measles Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 109. Beijing Institute of Biological Products Co., Ltd Live Attenuated Measles Vaccine Product Portfolio Table 110. Beijing Institute of Biological Products Co., Ltd Recent Development Table 111. Pfizer Company Information Table 112. Pfizer Business Overview Table 113. Pfizer Live Attenuated Measles Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 114. Pfizer Live Attenuated Measles Vaccine Product Portfolio Table 115. Pfizer Recent Development Table 116. Lanzhou Institute of Biological Products Co., Ltd Company Information Table 117. Lanzhou Institute of Biological Products Co., Ltd Business Overview Table 118. Lanzhou Institute of Biological Products Co., Ltd Live Attenuated Measles Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 119. Lanzhou Institute of Biological Products Co., Ltd Live Attenuated Measles Vaccine Product Portfolio Table 120. Lanzhou Institute of Biological Products Co., Ltd Recent Development Table 121. Merck Company Information Table 122. Merck Business Overview Table 123. Merck Live Attenuated Measles Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 124. Merck Live Attenuated Measles Vaccine Product Portfolio Table 125. Merck Recent Development Table 126. Novartis Company Information Table 127. Novartis Business Overview Table 128. Novartis Live Attenuated Measles Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 129. Novartis Live Attenuated Measles Vaccine Product Portfolio Table 130. Novartis Recent Development Table 131. Johnson & Johnson Company Information Table 132. Johnson & Johnson Business Overview Table 133. Johnson & Johnson Live Attenuated Measles Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 134. Johnson & Johnson Live Attenuated Measles Vaccine Product Portfolio Table 135. Johnson & Johnson Recent Development Table 136. Shanghai Institute of Biological Products Co., Ltd Company Information Table 137. Shanghai Institute of Biological Products Co., Ltd Business Overview Table 138. Shanghai Institute of Biological Products Co., Ltd Live Attenuated Measles Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 139. Shanghai Institute of Biological Products Co., Ltd Live Attenuated Measles Vaccine Product Portfolio Table 140. Shanghai Institute of Biological Products Co., Ltd Recent Development Table 141. Wuhan Institute of Biological Products Co., Ltd Company Information Table 142. Wuhan Institute of Biological Products Co., Ltd Business Overview Table 143. Wuhan Institute of Biological Products Co., Ltd Live Attenuated Measles Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 144. Wuhan Institute of Biological Products Co., Ltd Live Attenuated Measles Vaccine Product Portfolio Table 145. Wuhan Institute of Biological Products Co., Ltd Recent Development Table 146. Changchun Qijian Biological Products Co., Ltd Company Information Table 147. Changchun Qijian Biological Products Co., Ltd Business Overview Table 148. Changchun Qijian Biological Products Co., Ltd Live Attenuated Measles Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 149. Changchun Qijian Biological Products Co., Ltd Live Attenuated Measles Vaccine Product Portfolio Table 150. Changchun Qijian Biological Products Co., Ltd Recent Development Table 151. North America Live Attenuated Measles Vaccine Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 152. North America Live Attenuated Measles Vaccine Sales by Country (2021-2026) & (K Units) Table 153. North America Live Attenuated Measles Vaccine Sales Market Share by Country (2021-2026) Table 154. North America Live Attenuated Measles Vaccine Sales Forecast by Country (2027-2032) & (K Units) Table 155. North America Live Attenuated Measles Vaccine Sales Market Share Forecast by Country (2027-2032) Table 156. North America Live Attenuated Measles Vaccine Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 157. North America Live Attenuated Measles Vaccine Market Size by Country (2021-2026) & (US$ Million) Table 158. North America Live Attenuated Measles Vaccine Market Share by Country (2021-2026) Table 159. North America Live Attenuated Measles Vaccine Market Size Forecast by Country (2027-2032) & (US$ Million) Table 160. North America Live Attenuated Measles Vaccine Market Share Forecast by Country (2027-2032) Table 161. Europe Live Attenuated Measles Vaccine Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 162. Europe Live Attenuated Measles Vaccine Sales by Country (2021-2026) & (K Units) Table 163. Europe Live Attenuated Measles Vaccine Sales Market Share by Country (2021-2026) Table 164. Europe Live Attenuated Measles Vaccine Sales Forecast by Country (2027-2032) & (K Units) Table 165. Europe Live Attenuated Measles Vaccine Sales Market Share Forecast by Country (2027-2032) Table 166. Europe Live Attenuated Measles Vaccine Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 167. Europe Live Attenuated Measles Vaccine Market Size by Country (2021-2026) & (US$ Million) Table 168. Europe Live Attenuated Measles Vaccine Market Share by Country (2021-2026) Table 169. Europe Live Attenuated Measles Vaccine Market Size Forecast by Country (2027-2032) & (US$ Million) Table 170. Europe Live Attenuated Measles Vaccine Market Share Forecast by Country (2027-2032) Table 171. Asia-Pacific Live Attenuated Measles Vaccine Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 172. Asia-Pacific Live Attenuated Measles Vaccine Sales by Country (2021-2026) & (K Units) Table 173. Asia-Pacific Live Attenuated Measles Vaccine Sales Market Share by Country (2021-2026) Table 174. Asia-Pacific Live Attenuated Measles Vaccine Sales Forecast by Country (2027-2032) & (K Units) Table 175. Asia-Pacific Live Attenuated Measles Vaccine Sales Market Share Forecast by Country (2027-2032) Table 176. Asia-Pacific Live Attenuated Measles Vaccine Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 177. Asia-Pacific Live Attenuated Measles Vaccine Market Size by Country (2021-2026) & (US$ Million) Table 178. Asia-Pacific Live Attenuated Measles Vaccine Market Share by Country (2021-2026) Table 179. Asia-Pacific Live Attenuated Measles Vaccine Market Size Forecast by Country (2027-2032) & (US$ Million) Table 180. Asia-Pacific Live Attenuated Measles Vaccine Market Share Forecast by Country (2027-2032) Table 181. Latin America Live Attenuated Measles Vaccine Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 182. Latin America Live Attenuated Measles Vaccine Sales by Country (2021-2026) & (K Units) Table 183. Latin America Live Attenuated Measles Vaccine Sales Market Share by Country (2021-2026) Table 184. Latin America Live Attenuated Measles Vaccine Sales Forecast by Country (2027-2032) & (K Units) Table 185. Latin America Live Attenuated Measles Vaccine Sales Market Share Forecast by Country (2027-2032) Table 186. Latin America Live Attenuated Measles Vaccine Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 187. Latin America Live Attenuated Measles Vaccine Market Size by Country (2021-2026) & (US$ Million) Table 188. Latin America Live Attenuated Measles Vaccine Market Share by Country (2021-2026) Table 189. Latin America Live Attenuated Measles Vaccine Market Size Forecast by Country (2027-2032) & (US$ Million) Table 190. Latin America Live Attenuated Measles Vaccine Market Share Forecast by Country (2027-2032) Table 191. Middle East and Africa Live Attenuated Measles Vaccine Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 192. Middle East and Africa Live Attenuated Measles Vaccine Sales by Country (2021-2026) & (K Units) Table 193. Middle East and Africa Live Attenuated Measles Vaccine Sales Market Share by Country (2021-2026) Table 194. Middle East and Africa Live Attenuated Measles Vaccine Sales Forecast by Country (2027-2032) & (K Units) Table 195. Middle East and Africa Live Attenuated Measles Vaccine Sales Market Share Forecast by Country (2027-2032) Table 196. Middle East and Africa Live Attenuated Measles Vaccine Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 197. Middle East and Africa Live Attenuated Measles Vaccine Market Size by Country (2021-2026) & (US$ Million) Table 198. Middle East and Africa Live Attenuated Measles Vaccine Market Share by Country (2021-2026) Table 199. Middle East and Africa Live Attenuated Measles Vaccine Market Size Forecast by Country (2027-2032) & (US$ Million) Table 200. Middle East and Africa Live Attenuated Measles Vaccine Market Share Forecast by Country (2027-2032) Table 201. Key Raw Materials Table 202. Raw Materials Key Suppliers Table 203. Live Attenuated Measles Vaccine Distributors List Table 204. Live Attenuated Measles Vaccine Customers List Table 205. Research Programs/Design for This Report Table 206. Authors List of This Report Table 207. Secondary Sources Table 208. Primary Sources List of Figures Figure 1. Live Attenuated Measles Vaccine Image Figure 2. Global Live Attenuated Measles Vaccine Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Live Attenuated Measles Vaccine Market Size (2021-2032) & (US$ Million) Figure 4. Global Live Attenuated Measles Vaccine Sales (2021-2032) & (K Units) Figure 5. Liquid Image Figure 6. Global Liquid Sales YoY Growth (2021-2032) & (K Units) Figure 7. Powder Image Figure 8. Global Powder Sales YoY Growth (2021-2032) & (K Units) Figure 9. Global Live Attenuated Measles Vaccine Market Size Overview by Type (2021-2032) & (US$ Million) Figure 10. Global Live Attenuated Measles Vaccine Market Share by Type 2025 VS 2032 Figure 11. North America Live Attenuated Measles Vaccine Sales Market Share in Volume by Type in 2025 Figure 12. North America Live Attenuated Measles Vaccine Sales Market Share in Value by Type in 2025 Figure 13. Europe Live Attenuated Measles Vaccine Sales Market Share in Volume by Type in 2025 Figure 14. Europe Live Attenuated Measles Vaccine Sales Market Share in Value by Type in 2025 Figure 15. Asia-Pacific Live Attenuated Measles Vaccine Sales Market Share in Volume by Type in 2025 Figure 16. Asia-Pacific Live Attenuated Measles Vaccine Sales Market Share in Value by Type in 2025 Figure 17. Latin America Live Attenuated Measles Vaccine Sales Market Share in Volume by Type in 2025 Figure 18. Latin America Live Attenuated Measles Vaccine Sales Market Share in Value by Type in 2025 Figure 19. Middle East and Africa Live Attenuated Measles Vaccine Sales Market Share in Volume by Type in 2025 Figure 20. Middle East and Africa Live Attenuated Measles Vaccine Sales Market Share in Value by Type in 2025 Figure 21. Global Top 5 and 10 Live Attenuated Measles Vaccine Players Market Share by Revenue in 2025 Figure 22. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 23. Hospital Image Figure 24. Global Hospital Sales YoY Growth (2021-2032) & (K Units) Figure 25. Clinic Image Figure 26. Global Clinic Sales YoY Growth (2021-2032) & (K Units) Figure 27. Global Live Attenuated Measles Vaccine Market Size Overview by Application (2021-2032) & (US$ Million) Figure 28. Global Live Attenuated Measles Vaccine Market Share by Application 2025 VS 2032 Figure 29. North America Live Attenuated Measles Vaccine Sales Market Share in Volume by Application in 2025 Figure 30. North America Live Attenuated Measles Vaccine Sales Market Share in Value by Application in 2025 Figure 31. Europe Live Attenuated Measles Vaccine Sales Market Share in Volume by Application in 2025 Figure 32. Europe Live Attenuated Measles Vaccine Sales Market Share in Value by Application in 2025 Figure 33. Asia-Pacific Live Attenuated Measles Vaccine Sales Market Share in Volume by Application in 2025 Figure 34. Asia-Pacific Live Attenuated Measles Vaccine Sales Market Share in Value by Application in 2025 Figure 35. Latin America Live Attenuated Measles Vaccine Sales Market Share in Volume by Application in 2025 Figure 36. Latin America Live Attenuated Measles Vaccine Sales Market Share in Value by Application in 2025 Figure 37. Middle East and Africa Live Attenuated Measles Vaccine Sales Market Share in Volume by Application in 2025 Figure 38. Middle East and Africa Live Attenuated Measles Vaccine Sales Market Share in Value by Application in 2025 Figure 39. North America Live Attenuated Measles Vaccine Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 40. North America Live Attenuated Measles Vaccine Sales Share by Country: 2021 VS 2025 VS 2032 Figure 41. North America Live Attenuated Measles Vaccine Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 42. North America Live Attenuated Measles Vaccine Market Share by Country: 2021 VS 2025 VS 2032 Figure 43. Europe Live Attenuated Measles Vaccine Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 44. Europe Live Attenuated Measles Vaccine Sales Share by Country: 2021 VS 2025 VS 2032 Figure 45. Europe Live Attenuated Measles Vaccine Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 46. Europe Live Attenuated Measles Vaccine Market Share by Country: 2021 VS 2025 VS 2032 Figure 47. Asia-Pacific Live Attenuated Measles Vaccine Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 48. Asia-Pacific Live Attenuated Measles Vaccine Sales Share by Country: 2021 VS 2025 VS 2032 Figure 49. Asia-Pacific Live Attenuated Measles Vaccine Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 50. Asia-Pacific Live Attenuated Measles Vaccine Market Share by Country: 2021 VS 2025 VS 2032 Figure 51. Latin America Live Attenuated Measles Vaccine Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 52. Latin America Live Attenuated Measles Vaccine Sales Share by Country: 2021 VS 2025 VS 2032 Figure 53. Latin America Live Attenuated Measles Vaccine Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 54. Latin America Live Attenuated Measles Vaccine Market Share by Country: 2021 VS 2025 VS 2032 Figure 55. Middle East and Africa Live Attenuated Measles Vaccine Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 56. Middle East and Africa Live Attenuated Measles Vaccine Sales Share by Country: 2021 VS 2025 VS 2032 Figure 57. Middle East and Africa Live Attenuated Measles Vaccine Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 58. Middle East and Africa Live Attenuated Measles Vaccine Market Share by Country: 2021 VS 2025 VS 2032 Figure 59. Live Attenuated Measles Vaccine Value Chain Figure 60. Key Raw Materials Price Figure 61. Manufacturing Cost Structure Figure 62. Live Attenuated Measles Vaccine Production Mode & Process Figure 63. Direct Comparison with Distribution Share Figure 64. Distributors Profiles Figure 65. Years Considered Figure 66. Research Process Figure 67. Key Executives Interviewed

Scope & coverage.

Types
  • Liquid
  • Powder
Applications
  • Hospital
  • Clinic
Companies covered
  • GSK
  • Bavarian Nordic
  • CSL Limited
  • Emergent Biosolutions
  • Medimmune
  • Sanofi-Pasteur
  • Serum Institute of India
  • Beijing Institute of Biological Products Co., Ltd
  • Pfizer
  • Lanzhou Institute of Biological Products Co., Ltd
  • Merck
  • Novartis
  • Johnson & Johnson
  • Shanghai Institute of Biological Products Co., Ltd
  • Wuhan Institute of Biological Products Co., Ltd
  • Changchun Qijian Biological Products Co., Ltd

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Live Attenuated Measles Vaccine Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global Live Attenuated Measles Vaccine Sales Estimates and Forecasts (2021-2032)
  5. 1.3 Live Attenuated Measles Vaccine Market by Type
  6. 1.3.1 Liquid
  7. 1.3.2 Powder
  8. 1.4 Global Live Attenuated Measles Vaccine Market Size by Type
  9. 1.4.1 Global Live Attenuated Measles Vaccine Market Size Overview by Type (2021-2032)
  10. 1.4.2 Global Live Attenuated Measles Vaccine Historic Market Size Review by Type (2021-2026)
  11. 1.4.3 Global Live Attenuated Measles Vaccine Forecasted Market Size by Type (2027-2032)
  12. 1.5 Key Regions Market Size by Type
  13. 1.5.1 North America Live Attenuated Measles Vaccine Sales Breakdown by Type (2021-2026)
  14. 1.5.2 Europe Live Attenuated Measles Vaccine Sales Breakdown by Type (2021-2026)
  15. 1.5.3 Asia-Pacific Live Attenuated Measles Vaccine Sales Breakdown by Type (2021-2026)
  16. 1.5.4 South America Live Attenuated Measles Vaccine Sales Breakdown by Type (2021-2026)
  17. 1.5.5 Middle East and Africa Live Attenuated Measles Vaccine Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 Live Attenuated Measles Vaccine Industry Trends
  2. 2.2 Live Attenuated Measles Vaccine Industry Drivers
  3. 2.3 Live Attenuated Measles Vaccine Industry Opportunities and Challenges
  4. 2.4 Live Attenuated Measles Vaccine Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by Live Attenuated Measles Vaccine Revenue (2021-2026)
  2. 3.2 Global Top Players by Live Attenuated Measles Vaccine Sales (2021-2026)
  3. 3.3 Global Top Players by Live Attenuated Measles Vaccine Price (2021-2026)
  4. 3.4 Global Live Attenuated Measles Vaccine Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Live Attenuated Measles Vaccine Major Company Production Sites & Headquarters
  6. 3.6 Global Live Attenuated Measles Vaccine Company, Product Type & Application
  7. 3.7 Global Live Attenuated Measles Vaccine Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Live Attenuated Measles Vaccine Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Live Attenuated Measles Vaccine Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Live Attenuated Measles Vaccine Tier 1, Tier 2, and Tier 3
4 Live Attenuated Measles Vaccine Regional Status and Outlook
  1. 4.1 Global Live Attenuated Measles Vaccine Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global Live Attenuated Measles Vaccine Historic Market Size by Region
  3. 4.2.1 Global Live Attenuated Measles Vaccine Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global Live Attenuated Measles Vaccine Sales in Value by Region (2021-2026)
  5. 4.2.3 Global Live Attenuated Measles Vaccine Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global Live Attenuated Measles Vaccine Forecasted Market Size by Region
  7. 4.3.1 Global Live Attenuated Measles Vaccine Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global Live Attenuated Measles Vaccine Sales in Value by Region (2027-2032)
  9. 4.3.3 Global Live Attenuated Measles Vaccine Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 Live Attenuated Measles Vaccine by Application
  1. 5.1 Live Attenuated Measles Vaccine Market by Application
  2. 5.1.1 Hospital
  3. 5.1.2 Clinic
  4. 5.2 Global Live Attenuated Measles Vaccine Market Size by Application
  5. 5.2.1 Global Live Attenuated Measles Vaccine Market Size Overview by Application (2021-2032)
  6. 5.2.2 Global Live Attenuated Measles Vaccine Historic Market Size Review by Application (2021-2026)
  7. 5.2.3 Global Live Attenuated Measles Vaccine Forecasted Market Size by Application (2027-2032)
  8. 5.3 Key Regions Market Size by Application
  9. 5.3.1 North America Live Attenuated Measles Vaccine Sales Breakdown by Application (2021-2026)
  10. 5.3.2 Europe Live Attenuated Measles Vaccine Sales Breakdown by Application (2021-2026)
  11. 5.3.3 Asia-Pacific Live Attenuated Measles Vaccine Sales Breakdown by Application (2021-2026)
  12. 5.3.4 South America Live Attenuated Measles Vaccine Sales Breakdown by Application (2021-2026)
  13. 5.3.5 Middle East and Africa Live Attenuated Measles Vaccine Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 GSK
  2. 6.1.1 GSK Company Information
  3. 6.1.2 GSK Business Overview
  4. 6.1.3 GSK Live Attenuated Measles Vaccine Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 GSK Live Attenuated Measles Vaccine Product Portfolio
  6. 6.1.5 GSK Recent Developments
  7. 6.2 Bavarian Nordic
  8. 6.2.1 Bavarian Nordic Company Information
  9. 6.2.2 Bavarian Nordic Business Overview
  10. 6.2.3 Bavarian Nordic Live Attenuated Measles Vaccine Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 Bavarian Nordic Live Attenuated Measles Vaccine Product Portfolio
  12. 6.2.5 Bavarian Nordic Recent Developments
  13. 6.3 CSL Limited
  14. 6.3.1 CSL Limited Company Information
  15. 6.3.2 CSL Limited Business Overview
  16. 6.3.3 CSL Limited Live Attenuated Measles Vaccine Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 CSL Limited Live Attenuated Measles Vaccine Product Portfolio
  18. 6.3.5 CSL Limited Recent Developments
  19. 6.4 Emergent Biosolutions
  20. 6.4.1 Emergent Biosolutions Company Information
  21. 6.4.2 Emergent Biosolutions Business Overview
  22. 6.4.3 Emergent Biosolutions Live Attenuated Measles Vaccine Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 Emergent Biosolutions Live Attenuated Measles Vaccine Product Portfolio
  24. 6.4.5 Emergent Biosolutions Recent Developments
  25. 6.5 Medimmune
  26. 6.5.1 Medimmune Company Information
  27. 6.5.2 Medimmune Business Overview
  28. 6.5.3 Medimmune Live Attenuated Measles Vaccine Sales, Revenue and Gross Margin (2021-2026)
  29. 6.5.4 Medimmune Live Attenuated Measles Vaccine Product Portfolio
  30. 6.5.5 Medimmune Recent Developments
  31. 6.6 Sanofi-Pasteur
  32. 6.6.1 Sanofi-Pasteur Company Information
  33. 6.6.2 Sanofi-Pasteur Business Overview
  34. 6.6.3 Sanofi-Pasteur Live Attenuated Measles Vaccine Sales, Revenue and Gross Margin (2021-2026)
  35. 6.6.4 Sanofi-Pasteur Live Attenuated Measles Vaccine Product Portfolio
  36. 6.6.5 Sanofi-Pasteur Recent Developments
  37. 6.7 Serum Institute of India
  38. 6.7.1 Serum Institute of India Company Information
  39. 6.7.2 Serum Institute of India Business Overview
  40. 6.7.3 Serum Institute of India Live Attenuated Measles Vaccine Sales, Revenue and Gross Margin (2021-2026)
  41. 6.7.4 Serum Institute of India Live Attenuated Measles Vaccine Product Portfolio
  42. 6.7.5 Serum Institute of India Recent Developments
  43. 6.8 Beijing Institute of Biological Products Co., Ltd
  44. 6.8.1 Beijing Institute of Biological Products Co., Ltd Company Information
  45. 6.8.2 Beijing Institute of Biological Products Co., Ltd Business Overview
  46. 6.8.3 Beijing Institute of Biological Products Co., Ltd Live Attenuated Measles Vaccine Sales, Revenue and Gross Margin (2021-2026)
  47. 6.8.4 Beijing Institute of Biological Products Co., Ltd Live Attenuated Measles Vaccine Product Portfolio
  48. 6.8.5 Beijing Institute of Biological Products Co., Ltd Recent Developments
  49. 6.9 Pfizer
  50. 6.9.1 Pfizer Company Information
  51. 6.9.2 Pfizer Business Overview
  52. 6.9.3 Pfizer Live Attenuated Measles Vaccine Sales, Revenue and Gross Margin (2021-2026)
  53. 6.9.4 Pfizer Live Attenuated Measles Vaccine Product Portfolio
  54. 6.9.5 Pfizer Recent Developments
  55. 6.10 Lanzhou Institute of Biological Products Co., Ltd
  56. 6.10.1 Lanzhou Institute of Biological Products Co., Ltd Company Information
  57. 6.10.2 Lanzhou Institute of Biological Products Co., Ltd Business Overview
  58. 6.10.3 Lanzhou Institute of Biological Products Co., Ltd Live Attenuated Measles Vaccine Sales, Revenue and Gross Margin (2021-2026)
  59. 6.10.4 Lanzhou Institute of Biological Products Co., Ltd Live Attenuated Measles Vaccine Product Portfolio
  60. 6.10.5 Lanzhou Institute of Biological Products Co., Ltd Recent Developments
  61. 6.11 Merck
  62. 6.11.1 Merck Company Information
  63. 6.11.2 Merck Business Overview
  64. 6.11.3 Merck Live Attenuated Measles Vaccine Sales, Revenue and Gross Margin (2021-2026)
  65. 6.11.4 Merck Live Attenuated Measles Vaccine Product Portfolio
  66. 6.11.5 Merck Recent Developments
  67. 6.12 Novartis
  68. 6.12.1 Novartis Company Information
  69. 6.12.2 Novartis Business Overview
  70. 6.12.3 Novartis Live Attenuated Measles Vaccine Sales, Revenue and Gross Margin (2021-2026)
  71. 6.12.4 Novartis Live Attenuated Measles Vaccine Product Portfolio
  72. 6.12.5 Novartis Recent Developments
  73. 6.13 Johnson & Johnson
  74. 6.13.1 Johnson & Johnson Company Information
  75. 6.13.2 Johnson & Johnson Business Overview
  76. 6.13.3 Johnson & Johnson Live Attenuated Measles Vaccine Sales, Revenue and Gross Margin (2021-2026)
  77. 6.13.4 Johnson & Johnson Live Attenuated Measles Vaccine Product Portfolio
  78. 6.13.5 Johnson & Johnson Recent Developments
  79. 6.14 Shanghai Institute of Biological Products Co., Ltd
  80. 6.14.1 Shanghai Institute of Biological Products Co., Ltd Company Information
  81. 6.14.2 Shanghai Institute of Biological Products Co., Ltd Business Overview
  82. 6.14.3 Shanghai Institute of Biological Products Co., Ltd Live Attenuated Measles Vaccine Sales, Revenue and Gross Margin (2021-2026)
  83. 6.14.4 Shanghai Institute of Biological Products Co., Ltd Live Attenuated Measles Vaccine Product Portfolio
  84. 6.14.5 Shanghai Institute of Biological Products Co., Ltd Recent Developments
  85. 6.15 Wuhan Institute of Biological Products Co., Ltd
  86. 6.15.1 Wuhan Institute of Biological Products Co., Ltd Company Information
  87. 6.15.2 Wuhan Institute of Biological Products Co., Ltd Business Overview
  88. 6.15.3 Wuhan Institute of Biological Products Co., Ltd Live Attenuated Measles Vaccine Sales, Revenue and Gross Margin (2021-2026)
  89. 6.15.4 Wuhan Institute of Biological Products Co., Ltd Live Attenuated Measles Vaccine Product Portfolio
  90. 6.15.5 Wuhan Institute of Biological Products Co., Ltd Recent Developments
  91. 6.16 Changchun Qijian Biological Products Co., Ltd
  92. 6.16.1 Changchun Qijian Biological Products Co., Ltd Company Information
  93. 6.16.2 Changchun Qijian Biological Products Co., Ltd Business Overview
  94. 6.16.3 Changchun Qijian Biological Products Co., Ltd Live Attenuated Measles Vaccine Sales, Revenue and Gross Margin (2021-2026)
  95. 6.16.4 Changchun Qijian Biological Products Co., Ltd Live Attenuated Measles Vaccine Product Portfolio
  96. 6.16.5 Changchun Qijian Biological Products Co., Ltd Recent Developments
7 North America by Country
  1. 7.1 North America Live Attenuated Measles Vaccine Sales by Country
  2. 7.1.1 North America Live Attenuated Measles Vaccine Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America Live Attenuated Measles Vaccine Sales by Country (2021-2026)
  4. 7.1.3 North America Live Attenuated Measles Vaccine Sales Forecast by Country (2027-2032)
  5. 7.2 North America Live Attenuated Measles Vaccine Market Size by Country
  6. 7.2.1 North America Live Attenuated Measles Vaccine Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America Live Attenuated Measles Vaccine Market Size by Country (2021-2026)
  8. 7.2.3 North America Live Attenuated Measles Vaccine Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe Live Attenuated Measles Vaccine Sales by Country
  2. 8.1.1 Europe Live Attenuated Measles Vaccine Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe Live Attenuated Measles Vaccine Sales by Country (2021-2026)
  4. 8.1.3 Europe Live Attenuated Measles Vaccine Sales Forecast by Country (2027-2032)
  5. 8.2 Europe Live Attenuated Measles Vaccine Market Size by Country
  6. 8.2.1 Europe Live Attenuated Measles Vaccine Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe Live Attenuated Measles Vaccine Market Size by Country (2021-2026)
  8. 8.2.3 Europe Live Attenuated Measles Vaccine Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific Live Attenuated Measles Vaccine Sales by Country
  2. 9.1.1 Asia-Pacific Live Attenuated Measles Vaccine Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific Live Attenuated Measles Vaccine Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific Live Attenuated Measles Vaccine Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific Live Attenuated Measles Vaccine Market Size by Country
  6. 9.2.1 Asia-Pacific Live Attenuated Measles Vaccine Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific Live Attenuated Measles Vaccine Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific Live Attenuated Measles Vaccine Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America Live Attenuated Measles Vaccine Sales by Country
  2. 10.1.1 South America Live Attenuated Measles Vaccine Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America Live Attenuated Measles Vaccine Sales by Country (2021-2026)
  4. 10.1.3 South America Live Attenuated Measles Vaccine Sales Forecast by Country (2027-2032)
  5. 10.2 South America Live Attenuated Measles Vaccine Market Size by Country
  6. 10.2.1 South America Live Attenuated Measles Vaccine Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America Live Attenuated Measles Vaccine Market Size by Country (2021-2026)
  8. 10.2.3 South America Live Attenuated Measles Vaccine Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa Live Attenuated Measles Vaccine Sales by Country
  2. 11.1.1 Middle East and Africa Live Attenuated Measles Vaccine Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa Live Attenuated Measles Vaccine Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa Live Attenuated Measles Vaccine Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa Live Attenuated Measles Vaccine Market Size by Country
  6. 11.2.1 Middle East and Africa Live Attenuated Measles Vaccine Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa Live Attenuated Measles Vaccine Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa Live Attenuated Measles Vaccine Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 Live Attenuated Measles Vaccine Value Chain Analysis
  2. 12.1.1 Live Attenuated Measles Vaccine Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 Live Attenuated Measles Vaccine Production Mode & Process
  7. 12.2 Live Attenuated Measles Vaccine Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 Live Attenuated Measles Vaccine Distributors
  10. 12.2.3 Live Attenuated Measles Vaccine Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst